United Therapeutics Corp. (UTHR)
591.11
-2.20
(-0.37%)
USD |
NASDAQ |
Nov 13, 16:00
591.11
0.00 (0.00%)
After-Hours: 19:59
United Therapeutics Enterprise Value : 23.08B for Nov. 12, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| November 12, 2026 | 23.08B |
| November 11, 2026 | 23.18B |
| November 10, 2026 | 22.88B |
| November 09, 2026 | 22.62B |
| November 06, 2026 | 21.75B |
| November 05, 2026 | 21.91B |
| November 04, 2026 | 23.72B |
| November 03, 2026 | 23.42B |
| November 02, 2026 | 23.20B |
| October 30, 2026 | 23.31B |
| October 29, 2026 | 23.09B |
| October 28, 2026 | 22.79B |
| October 27, 2026 | 22.99B |
| October 26, 2026 | 23.06B |
| October 23, 2026 | 22.83B |
| October 22, 2026 | 22.72B |
| October 21, 2026 | 21.81B |
| October 20, 2026 | 21.41B |
| October 19, 2026 | 20.95B |
| October 16, 2026 | 20.53B |
| October 15, 2026 | 20.88B |
| October 14, 2026 | 20.82B |
| October 13, 2026 | 20.96B |
| October 12, 2026 | 21.25B |
| October 09, 2026 | 21.21B |
| Date | Value |
|---|---|
| October 08, 2026 | 20.51B |
| October 07, 2026 | 21.03B |
| October 06, 2026 | 20.89B |
| October 05, 2026 | 20.67B |
| October 02, 2026 | 20.89B |
| October 01, 2026 | 22.15B |
| September 30, 2026 | 20.90B |
| September 29, 2026 | 17.89B |
| September 28, 2026 | 18.06B |
| September 25, 2026 | 17.63B |
| September 24, 2026 | 17.49B |
| September 23, 2026 | 18.22B |
| September 22, 2026 | 18.57B |
| September 21, 2026 | 18.38B |
| September 18, 2026 | 18.45B |
| September 17, 2026 | 18.56B |
| September 16, 2026 | 18.61B |
| September 15, 2026 | 18.69B |
| September 14, 2026 | 18.79B |
| September 11, 2026 | 18.55B |
| September 10, 2026 | 18.84B |
| September 09, 2026 | 18.97B |
| September 08, 2026 | 18.59B |
| September 04, 2026 | 18.15B |
| September 03, 2026 | 18.26B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Liquidia Corp. | 4.988B |
| Alnylam Pharmaceuticals, Inc. | 20.38B |
| Exelixis, Inc. | 16.36B |
| Gilead Sciences, Inc. | 226.62B |
| Insmed, Inc. | 25.50B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | 258.60M |
| Revenue (Quarterly) | 832.50M |
| Total Expenses (Quarterly) | 573.90M |
| EPS Diluted (Quarterly) | 5.709 |
| Gross Profit Margin (Quarterly) | 88.10% |
| Profit Margin (Quarterly) | 31.06% |
| Earnings Yield | 4.48% |
| Operating Earnings Yield | 5.06% |
| Normalized Earnings Yield | 4.304 |